Ostiio

Leveraging the Body's Natural Healing Ability to Treat Craniofacial Abnormalities

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Philadelphia, PA, US
  • Currency USD
  • Founded February 2017
  • Employees 4
  • Incorporation Type LLC
  • Website ostiio.com

Company Summary

Each year >200K children are born with conditions that restrict growth of their skull or lower jaw. Left untreated, these conditions result in serious complications – impaired neurologic development, difficulty breathing and inability to eat. But the treatments themselves are complex/traumatic. Ostiio is developing an integrated therapy that solves the main limitations of today's treatments to improve patient outcomes while reducing hospital cost

Team

  • Chief Technology Officer

    Ari is a Plastic Surgery Resident at the Hospital of the University of Pennsylvania (HUP) and also worked as a Clinical Research Fellow for the Divisions of Plastic Surgery at HUP and the Children’s Hospital of Philadelphia. Ari's strong clinical and translational background gives Ostiio unique insight into the complexities associated with craniofacial distraction and methods to improve outcomes.

  • Chief Executive Officer

    Jessica is an accomplished MedTech leader with a track record of building emerging businesses within large corporates (JNJ, SNN, ABT, BDX). Her career has encompassed a diverse background across therapy spaces, technologies, and functional leadership roles. She has led cross-functional teams to build and execute global operational plans that supported a diverse portfolio of product clearances/approvals and their subsequent commercialization.

  • Chief Medical Officer

    Jesse is Chief of the Division of Plastic and Reconstructive Surgery at the world-renowned Children’s Hospital of Philadelphia (CHOP) and a specialist and key opinion leader in the treatment of children with craniofacial differences. He is passionate about developing innovative treatment strategies to optimize results for his patients and pioneered the use of distraction osteogenesis to treat impaired growth of the craniomaxillofacial skeleton.

  • Brett Nowlin
    Head of Quality & Product Development

    Brett brings extensive experience in the design, development and manufacture of medical devices across multiple therapy spaces and business environments (small entrepreneurial VC-funded to large Fortune 500 corporate). These experiences have given him strong insight into what it takes to bring a safe and efficacious product to market and to sustain that performance post-launch.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free